Last updated: July 20, 2026
JANSSEN PHARMACEUTICALS, INC. v. MACLEODS PHARMACEUTICALS, LTD. (3:24-cv-04564): Litigation Summary, Claims at Issue, and Generic Risk Timeline
What court and case details define JANSSEN v. Macleods (3:24-cv-04564)?
Case caption: Janssen Pharmaceuticals, Inc. v. Macleods Pharmaceuticals, Ltd.
Docket: 3:24-cv-04564
Court: Not specified in the provided input
Parties: Janssen Pharmaceuticals, Inc. (plaintiff) vs. Macleods Pharmaceuticals, Ltd. (defendant)
Filing year: 2024 (from docket number prefix “3:24-”)
No claim-specific docket events, patent numbers, asserted claims, venue details (district/judge/magistrate), or procedural posture are included in the provided input. Without those elements, a complete and accurate litigation summary cannot be produced.
What patents are asserted in JANSSEN v. MACLEODS (3:24-cv-04564)?
The asserted patent list is not included in the provided input. Patent identifiers (US application/publication numbers; US patents; asserted claims; expiration dates) are required to summarize:
- which Orange Book-listed drug and NDA/ANDA is at issue,
- whether the case is a Paragraph IV Hatch-Waxman suit,
- and how strong the asserted estate is versus the claimed generic.
No patent numbers are available from the input, so this section cannot be completed.
What is the litigation procedural posture for JANSSEN v. MACLEODS (3:24-cv-04564)?
The input does not provide any docket events, including:
- complaint filing date,
- answer and invalidity/contentions schedule,
- Markman order status,
- discovery schedule,
- claim construction timeline,
- summary judgment motions,
- trial setting,
- settlement dates (if any),
- or consent injunction terms (if applicable).
When do exclusivity and generic-entry windows become actionable under this docket?
Actionable timing in Hatch-Waxman litigation depends on:
- the NDA/Orange Book reference product,
- the patent expiration and any pediatric exclusivity,
- market exclusivity and 30-month stay triggers,
- the certification type (Paragraph IV),
- and any settlement or entry dates.
None of these data points are present in the provided input, so a reliable exclusivity and launch timeline cannot be produced.
How does this case affect Paragraph IV risk for Macleods’ generic strategy?
Generic-entry risk analysis requires at least:
- the drug product and strength/dosage form,
- the specific ANDA and Paragraph IV certifications,
- whether the court has issued a preliminary injunction or entered a permanent injunction,
- and whether the case ended in settlement with an agreed design-around.
No ANDA details, certifications, or remedies are included in the input.
What settlement outcomes or injunction terms are tied to 3:24-cv-04564?
Settlement outcomes require docket-specific facts:
- whether a settlement was reached,
- whether the parties agreed to a launch date,
- whether the settlement included a covenant not to sue,
- whether the parties entered a consent injunction,
- and whether there were appellate outcomes.
No settlement or injunction terms are included in the provided input.
Which drug and regulatory pathway does this litigation target?
To link litigation to FDA regulatory status, the analysis must identify the:
- Orange Book listing (NDA and strength/formulation),
- ANDA number,
- FDA approval date and application type,
- and whether there is a biosimilar pathway (if biologics are involved).
The input provides only party names and docket number, with no drug/product identification.
How strong is Janssen’s patent estate relative to Macleods’ infringement positions in this case?
Patent strength in a specific case requires:
- asserted claim scope,
- claim construction outcomes,
- infringement theory (literal vs. equivalents),
- invalidity grounds (anticipation/obviousness/indefiniteness/enablement),
- prosecution history estoppel or disclaimers,
- and prior art.
No asserted claims or invalidity arguments are included in the input, so strength cannot be evaluated.
Key Takeaways
- The provided information identifies the parties and docket number (3:24-cv-04564) but contains no patent identifiers, asserted claims, procedural history, or remedy/timing outcomes.
- A complete litigation summary and business-grade analysis cannot be generated from the provided input alone.
FAQs
- What is a Hatch-Waxman Paragraph IV filing and how does it connect to court dockets like 3:24-cv-04564?
- What documents typically contain the asserted patent list in a Janssen v. generic-company case?
- How do claim construction (Markman) outcomes change infringement and validity risk in ANDA litigation?
- What factors determine whether a generic launch is stayed for 30 months in Paragraph IV cases?
- What settlement terms most commonly appear in consent injunctions between branded and generic companies?
References (APA)
No sources were provided in the input, and no docket-specific documents or patent records were cited.
